So an obvious question that we ask ourselves whenever we're trying a new therapy or a new combination therapy is, what is the patient going to experience? In other words, what are the side effects that you could expect from any kind of therapy? And this is incredibly important in patients with our current cancer as we see that even in patients that have complete responses, this is likely palliative palliative therapy and not curative intent. And so how a patient tolerates in therapy is incredibly important uh to our choice uh of possible therapies. And so if you look at Uh, the original artistry one trial and the combination arms, so they had about 160 patients that went on combination with various kinds of diseases. And, and so we have a reasonably sized database to look at a side effect profile, uh, to be able to compare and expect on artistry 7. by far and away the most common side effects were low grade, grade 1 and 2 fever and chills that happened with infusion. Uh, of the, uh, nvolleukin and could happen for any time over the course of the week that the patients were getting the infusions and even for a couple of days afterwards. Um, a number of patients, uh, experienced grade 1 to 2 or even grade 3 neutropenia when receiving them leukin. Um, some had nausea, some had hypotension, but, uh, very mild hypertension, grade 1 and grade 2. There were no capillary leak events reported within artistry 1, which is very important considering the history of giving idociL2 to our patients, uh. I think the other important factor to look at is how many patients discontinued therapy because of treatment-related adverse events, and this is always an important number. And, and within the artist through one trial, only 4% of patients in the combination therapy actually stopped therapy because of treatment-related adverse events, and that is uh generally comparable if not a little better to what we see with chemotherapy and large phase 3 trials, which leads us to think that this will be a well tolerated combination.
Presenter
